Literature DB >> 9922191

MR imaging patterns of gadolinium retention within liver neoplasms.

M S Peterson1, T Murakami, R L Baron.   

Abstract

BACKGROUND: To determine the spectrum of appearances of gadolinium retention within cholangiocarcinoma (CCA) and other liver neoplasms.
METHODS: Two hundred ten patients underwent hepatic magnetic resonance imaging (MRI) at 1.5 T with precontrast T1- and T2-weighted spin-echo (SE) images and delayed Gd-DTPA- or gadoteridol- (0.1 mmol/kg) enhanced T1-weighted SE images. Postcontrast images were evaluated for lesions suspicious for tumors, and lesion signal intensity was characterized as homogeneously or heterogeneously hypo-, iso-, mildly hyper-, or markedly hyperintense to liver. Data from 94 patients with benign or malignant neoplasms are presented.
RESULTS: Imaging demonstrated 237 malignant neoplasms (121 hepatocellular carcinoma [HCC], 26 CCA, 17 colon carcinoma metastases, 73 other tumors) and 28 benign neoplasms (22 hemangioma, six focal nodular hyperplasia [FNH]). One hundred forty malignant lesions appeared as homogeneous postcontrast (29 hypointense, 75 isointense, 17 mildly hyperintense, 19 markedly hyperintense) and 97 as heterogeneous (15 isointense, 50 mildly hyperintense, 32 markedly hyperintense). Malignant lesions showing homogeneous, mildly or markedly hyperintense signal intensity postcontrast included 10 CCA, seven HCC, six epithelioid hemangioendothelioma, eight neuroendocrine tumor metastases, three adenocarcinoma metastases of unknown origin, and one breast carcinoma metastasis. Hemangiomas appeared as homogeneous postcontrast in 19 lesions (six isointense, one mildly hyperintense, 12 markedly hyperintense) and as heterogeneous in three lesions (markedly hyperintense). FNH appeared as homogeneous postcontrast in one lesion (isointense) and as heterogeneous in five lesions (one isointense, four mildly hyperintense).
CONCLUSION: Homogeneous gadolinium retention on delayed postcontrast images of malignant hepatic neoplasms is seen in a high percentage of CCA lesions and less commonly with other neoplasms.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9922191     DOI: 10.1007/s002619900410

Source DB:  PubMed          Journal:  Abdom Imaging        ISSN: 0942-8925


  7 in total

1.  Extracellular contrast agent-enhanced MRI: 15-min delayed phase may improve the diagnostic performance for hepatocellular carcinoma in patients with chronic liver disease.

Authors:  Si Eun Lee; Chansik An; Shin Hye Hwang; Jin-Young Choi; Kyunghwa Han; Myeong-Jin Kim
Journal:  Eur Radiol       Date:  2017-11-13       Impact factor: 5.315

Review 2.  Cholangiocarcinoma: modern advances in understanding a deadly old disease.

Authors:  Harmeet Malhi; Gregory J Gores
Journal:  J Hepatol       Date:  2006-09-25       Impact factor: 25.083

Review 3.  Diagnosis and initial management of cholangiocarcinoma with obstructive jaundice.

Authors:  Takashi Tajiri; Hiroshi Yoshida; Yasuhiro Mamada; Nobuhiko Taniai; Shigeki Yokomuro; Yoshiaki Mizuguchi
Journal:  World J Gastroenterol       Date:  2008-05-21       Impact factor: 5.742

4.  Added value of ancillary imaging features for differentiating scirrhous hepatocellular carcinoma from intrahepatic cholangiocarcinoma on gadoxetic acid-enhanced MR imaging.

Authors:  Seo-Youn Choi; Young Kon Kim; Ji Hye Min; Tae Wook Kang; Woo Kyoung Jeong; Soohyun Ahn; Hojeong Won
Journal:  Eur Radiol       Date:  2018-01-15       Impact factor: 5.315

5.  Magnetic Resonance Imaging of cholangiocarcinoma.

Authors:  Katrina A Vanderveen; Hero K Hussain
Journal:  Cancer Imaging       Date:  2004-04-06       Impact factor: 3.909

Review 6.  Current status of intrahepatic cholangiocarcinoma.

Authors:  Jian Yang; Lu-Nan Yan
Journal:  World J Gastroenterol       Date:  2008-11-07       Impact factor: 5.742

Review 7.  Cholangiocarcinoma: Biology, Clinical Management, and Pharmacological Perspectives.

Authors:  Rocio I R Macias
Journal:  ISRN Hepatol       Date:  2014-02-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.